Astellas, Drug Prices & Medicare Spending
Astellas manufactures 6 drugs tracked by Medicare Part D with total spending of $2.3B.
Astellas Drugs, Ranked by Medicare Spending
| # | Drug | Generic Name | Cost/Claim | Generic? |
|---|---|---|---|---|
| 1 | Myrbetriq | Mirabegron | $180.00 | Yes |
| 2 | Prograf | Tacrolimus | $229.00 | Yes |
| 3 | Xospata | Gilteritinib | $19,500.00 | Yes |
| 4 | Vesicare | Solifenacin | $94.00 | Yes |
| 5 | Cresemba | Isavuconazonium | $3,441.00 | Yes |
| 6 | Veozah | Fezolinetant | $206.00 | Yes |
Frequently Asked Questions
Astellas manufactures 6 drugs tracked by Medicare Part D, with total annual spending of $2.3B.
Xospata (Gilteritinib) is the most expensive at $19,500.00 per claim.
6 of 6 Astellas drugs (100%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.
The this entity record above pulls directly from CMS Medicare Part D Drug Spending data. What follows is the per-entity context — how this entity sits in the broader U.S. Medicare prescription-drug pricing distribution and which underlying factors drive the headline numbers.
Every number on this page links back to CMS Medicare Part D Drug Spending data; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. prescription drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.
Source: CMS Medicare Part D Spending, 2026.